Immix Biopharma enters ATM facility to sell up to $5M in common stock

Immix Biopharma, Inc.

ATM Sales Agreement with ThinkEquity LLC for up to $5,000,000 of common stock.
Shares sold at market prices; fixed commission of 3.75% of gross proceeds.
Offering made under existing S-3 shelf registration statement declared effective Jan 2023.
Expense deposit of $15,000 paid; legal fee reimbursement up to $50,000.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Immix Biopharma, Inc. entered into Sales Agreement with ThinkEquity LLC valued at up to $5,000,000 (effective 2023-03-22).

Action: entry
Agreement: atm program
Counterparty: ThinkEquity LLC
Value: up to $5,000,000
Effective: 2023-03-22

Exact text from the filing

On March 22, 2023, Immix Biopharma, Inc. (the “Company”) entered into an ATM Sales Agreement (the “Sales Agreement”) with ThinkEquity LLC (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $5,000,000

View on SEC.gov

Browse all material agreements →

Immix Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-008484

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.